IL1R1抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using IL1R1 mouse mAb against Hela (1) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using IL1R1 mouse mAb (green) and negative control (red).    

  
  

Interleukin-1 receptor type 1 (IL1R1) is a key component of the interleukin-1 (IL-1) signaling pathway, which plays a central role in regulating inflammatory and immune responses. As a transmembrane receptor, IL1R1 binds to IL-1 ligands, including IL-1α and IL-1β, initiating downstream pro-inflammatory signaling cascades such as NF-κB and MAPK pathways. Dysregulation of IL-1 signaling is implicated in various inflammatory diseases, autoimmune disorders (e.g., rheumatoid arthritis), and metabolic conditions (e.g., type 2 diabetes), making IL1R1 a therapeutic target.

IL1R1 antibodies are biologic agents designed to block IL-1 ligand-receptor interactions or receptor activation. These antibodies can neutralize IL1R1 activity, thereby suppressing excessive inflammation and tissue damage. For example, Anakinra, an IL-1 receptor antagonist, indirectly targets this pathway, while monoclonal antibodies like canakinumab (targeting IL-1β) highlight the clinical relevance of modulating IL-1 signaling. Preclinical studies using IL1R1-specific antibodies have demonstrated efficacy in reducing inflammation in models of arthritis, sepsis, and cardiovascular diseases.

Therapeutic IL1R1 antibodies aim to balance immune suppression with safety, as prolonged inhibition may increase infection risks. Research continues to optimize antibody specificity, delivery, and half-life. Beyond therapeutics, IL1R1 antibodies serve as critical tools for studying IL-1 biology, receptor distribution, and signaling mechanisms. Their development underscores the importance of IL-1 pathways in human disease and the potential for targeted immunomodulation.